Latest Conference Articles

Markley describes the importance of monitoring bone health in patients with IBD and celiac disease and explains her research showing low screening rates.

In this interview at Fall Clinical, Song highlights takeaways from his portion of the session ‘30 Tips in 30 Minutes.’

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Song interviewed with the team regarding his session, discussing recent data on IL-23 inhibition in patients with psoriasis.

Alexis spoke in this segment of his Fall Clinical interview on takeaways from his presentation titled ‘Melasma and Other Hyperpigmentation Disorders.’

In this Fall Clinical interview, Alexis highlights several tips for clinicians covered in his session at the conference titled ‘30 Tips in 30 Minutes.’

This interview with Prince Adotama, MD, at Fall Clinical highlights several takeaways from his session on treating bullous pemphigoid.

This interview at Fall Clinical highlights a session on clinical pearls related to diagnosing prurigo nodularis in patients with skin of color.

Pooled results from two Phase 3 trials show DFD-29 achieved a 62.7% IGA success rate and significantly greater lesion reduction than both doxycycline and placebo.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

Lilly's lebrikizumab-lbkz treatment, used once every 8 weeks, resulted in durable disease control in moderate-to-severe atopic dermatitis.

This interview highlights the takeaways from Nestor’s Fall Clinical session titled ‘What Did 2025 Bring to the Table in Dermatology?’

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.